
Elan Management Cleared Of Wrongdoing
An external review has cleared Elan Corp (Ireland) of any wrongdoing following "a number of matters" brought to the Board?s attention by some directors concerning corporate governance practices.
An external review has cleared Elan Corp (Ireland) of any wrongdoing following “a number of matters” brought to the Board’s attention by some directors concerning corporate governance practices. The review, conducted by US law firm McKenna Long & Aldridge, found “no legal breaches or other wrongdoings of any nature” by Elan management, members of its Board of Directors or its advisors. According to a company 
With it, the Elan Board has also accepted the report’s recommendations, including “considering the feasibility of voluntarily complying with US domestic reporting requirements notwithstanding Elan’s status as a foreign private issuer and adopting a US ‘best practices’ conflicts policy”. Elan added that the close of the investigation will bring “renewed” focus to the company.
Although the press statement provides no details about the matters investigated, a number of other sources (
According to the Elan statement, Bryson and Schuler have “expressed their satisfaction with the outcome of the McKenna process” and have agreed to suspend the Irish High Court Proceedings. They will also resign from the Board within 90 days.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





